Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Invitae Corp (NY: NVTA )

55.21 USD +2.08 (+3.91%)
Official Closing Price Updated: 8:00 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Invitae Corp

< Previous 1 2 3 4 5 6 7 8 9 Next >
Invitae Announces Pricing of Public Offering of Common Stock
Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares... 
From PR Newswire
Invitae Announces Proposed Public Offering of Common Stock
Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and... 
From PR Newswire
Leading Biopharmaceutical Companies Select Invitae to Develop Standardized Panel to Detect Molecular Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
-- Project aims to standardize MRD data generation, assessment and accelerate AML clinical trial programs bringing novel therapies to patients in need faster -- 
From PR Newswire
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform
New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care 
From GlobeNewswire News Releases
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
-- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific -- 
From PR Newswire
Invitae to Present at the 39th Annual J.P. Morgan Healthcare Conference
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan... 
From PR Newswire
Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster
-- Artificial intelligence-powered technology helps bring the benefits of comprehensive clinical sequencing to patient care while maintaining exceptional accuracy and reproducibility -- 
From PR Newswire
Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium
Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and... 
From PR Newswire
New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients
-- Study finds nearly 1 in 10 show genetic changes with established clinical management recommendations, potential eligibility for precision therapies and/or clinical treatment trials -- 
From PR Newswire
Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1
Genetic testing, educational materials and counseling offered at no charge to patients 
From GlobeNewswire News Releases
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
-- Strong results driven by comprehensive menu, customer relationships and consistent execution -- 
From PR Newswire
Research Highlights Frequency of Genetic Risk Factors Among Men with Prostate Cancer, Suggests Role for Broader Screening
Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human Genetics (ASHG) Virtual Meeting found one in ten men with prostate cancer harbor genetic... 
From PR Newswire
Invitae to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a... 
From PR Newswire
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
From GlobeNewswire News Releases
New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencing
--Study suggests all cancer patients could benefit from both germline and somatic testing, utility of germline testing in identifying additional treatment options for cancer patients -- 
From PR Newswire
Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and Large-Market Indications
Taysha Gene Therapies Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the... 
From Business Wire News Releases
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
-- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility -- 
From PR Newswire
Invitae Appoints Kimber Lockhart to its Board of Directors
-- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur -- 
From PR Newswire
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
- Early diagnosis through genetic testing may lead to improved long-term outcomes for patients with neurotransmitter disorders, including AADC deficiency - 
From PR Newswire
Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer
-- 1 in 9 men will be diagnosed with prostate cancer in their lifetime -- 
From PR Newswire
Invitae to Participate in the Morgan Stanley Virtual Global Healthcare Conference
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate in a fireside chat at the 18th Annual Morgan Stanley... 
From PR Newswire
Civilization Ventures Announces $35M Second Fund
Civilization Ventures is announcing the close of its second fund following the successful investment of Fund I in 2017, where the firm had major portfolio exits with the public listing of gene therapy... 
From Business Wire News Releases
Invitae Reports Inducement Grants Under NYSE Rule 303A.08
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units ("RSUs") to Kenneth D. Knight, Invitae's new Chief Operating Officer and... 
From PR Newswire
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
-- Introduced expanded services and support for transition to telehealth across customer types -- 
From PR Newswire
Invitae to Announce Second Quarter 2020 Financial Results on August 4, 2020
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference... 
From PR Newswire
SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - NGHC, DCOM, NVTA
From ACCESSWIRE
INVESTIGATION ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - GARS, NVTA, REXN
From ACCESSWIRE
ALERT: Halper Sadeh LLP Continues to Investigate Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - NGHC, NVTA, GRUB
From ACCESSWIRE
Moore Kuehn Encourages DCOM, MYOS, ADSW, and NVTA Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are... 
From PR Newswire
SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - NVTA, MYOS, DCOM
From ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.